Piper Jaffray Downgrades Alcobra Ltd. (ADHD) to Neutral

September 29, 2016 4:09 PM EDT
Get Alerts ADHD Hot Sheet
Price: $2.33 -0.43%

Rating Summary:
    2 Buy, 8 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade ADHD Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Piper Jaffray downgraded Alcobra Ltd. (NASDAQ: ADHD) from Overweight to Neutral with a price target of $3.00 (from $10.00).

Analyst Charles Duncan commented, "Alcobra announced its Metadoxine XR (MDX) program was placed on full clinical hold by the FDA. The company believes this involves a neurological safety signal in rodent studies. However, until we learn more about the reasons for the hold and potential relevance to humans, we have low visibility on: timing of a response, impact on the potential for a positive outcome from the Phase III MEASURE study, and the regulatory path forward for MDX. In particular, this news increases clinical risk as only a portion of the targeted MEASURE population is evaluable for efficacy per protocol, thus reducing the probability of demonstrating an impact. That said, this may not be terminal for MDX in the longer term. Overall, given the near-term increase in clinical risk and timeline uncertainty we see across all potential MDX indications, we are stepping to the sidelines with a Neutral and cutting our target to $3."

For an analyst ratings summary and ratings history on Alcobra Ltd. click here. For more ratings news on Alcobra Ltd. click here.

Shares of Alcobra Ltd. closed at $4.62 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Downgrades

Related Entities

Piper Jaffray, Charles Duncan

Add Your Comment